Glycosylation Analysis

Glycosylation Analysis Services Market by Company Size (Small, Mid- sized and Large), Analytical Techniques (Spectroscopy, Chromatography, Microarrays and Electrophoresis) and Key Geographical Regions (North America (US, Canada), Europe (Italy, Spain, Germany, France, UK) and Asia- Pacific (India, Japan, China)): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    June 2021

  • Pages
    342

  • View Count
    5801

  • Buy Now

Example Insights

Glycosylation-Analysis-Services-Market-Context Glycosylation-Analysis-Services-Market-Services-Providers Glycosylation-Analysis-Services-Market-Distribution-by-Type-of-Analytical-Technique Glycosylation-Analysis-Services-Market-Geographical-Distribution
Glycosylation-Analysis-Services-Market-3D-Bubble-Analysis Glycosylation-Analysis-Services-Market-List-of-Surface-Glycan Glycosylation-Analysis-Services-Market-Distribution-by-Phase-of-Development Glycosylation-Analysis-Services-Market-Grant-Analysis
Glycosylation-Analysis-Services-Market-Partnerships-and-Collaborations Glycosylation-Analysis-Services-Market-Mergers-and-Acquisitions Glycosylation-Analysis-Services-Market-Opportunity  

 

Overview

Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as one of the fastest growing classes of pharmacologically active molecules. Till date, over 67% of biologics and 80% of biosimilars approved by the FDA, feature some form of glycosylation. In fact, the pipeline of such interventions is also growing at a commendable pace (CAGR of over 20%). It is important to highlight that for higher eukaryotes, such as humans, glycosylation of certain biomolecules is not only important from the functional perspective, but it also imparts beneficial pharmacological properties, which influence efficacy, solubility, stability, and antigen binding. Further, glycans represent a promising class of biomarkers that are useful for disease prognosis, diagnosis, and assist in the prediction of treatment efficacy. In this context, several tumor-associated (aberrant) glycan molecules (such as Tn, sialyl-T and sialyl-Tn), as well as virulent glycoproteins on pathogenic viral envelopes (such as the glycan shield associated with the SARS-CoV-2 spike glycoprotein), are presently being investigated as viable therapeutic targets.

Given the complexities associated with glycan analysis, it is difficult for non-specialist researchers and therapy developers, to effectively analyze this aspect of biomolecules. Moreover, the associated analytical procedures are further complicated by multi-step analytical protocols and technically demanding expertise, which eventually lead to contamination of samples and lack of reproducibility in test results. Recent evolution in the approach (such as the use of orthogonal techniques and the middle-up strategy) to analyzing data generated from the diverse bioanalytical techniques used in glycan profiling, necessitate extensive domain expertise. Consequently, drug developers and medical researchers are increasingly relying on contract service providers with the necessary analytical expertise and technical infrastructure, for their glycan analysis needs. Currently, more than 130 industry and non- industry players claim to be actively providing glycan analysis services. In the recent past, a number of stakeholders in the services sector, have forged strategic alliances with and / or acquired other players offering glycan analysis or related services, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their respective offerings, we believe the contract services market for glycan analysis is likely to grow at a steady pace, till 2030.

Scope of the Report

The “Glycosylation Analysis Services Market, 2021- 2030” report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the market, over the next decade. The study underlines an in-depth analysis of the various services offered for assessing glycosylation related attributes, in biopharmaceutical, biomedical and clinical samples. Amongst other elements, the report includes:

  • A detailed review of the overall landscape of the glycan analysis services market, highlighting the contributions of industry players, along with the information on their year of establishment, company size, geographical location of headquarters, type of service(s) offered (glycan profiling and heterogeneity analysis, glycosylation site mapping and occupancy analysis, site- specific glycosylation analysis, glycan structure analysis, monosaccharide quantification analysis and protein- glycan binding analysis), type of glycoconjugate and glycan analyzed (N- glycan, O- glycan and glycolipid), type of sample analyzed (biotherapeutics and cellular), type of analyte processed (intact glycoprotein, glycopeptide, released glycan, monosaccharide and polysaccharide), type of analytical technique used (chromatography, spectroscopy, electrophoresis and microarray- based technique), application area (R&D / early- stage drug development and in- process drug development) It also provides information on the additional services offered (peptide mapping, post- translational modification analysis, protein terminal sequencing and glycan / glycoconjugate synthesis), and availability of synthetic glycans and analytical kits / tests.  In addition, it provides information on the type of glycoanalytical service offered and type of technique used by non-industry players.
  • A region-wise company competitiveness analysis, highlighting the most prominent glycan analysis service providers, based on their supplier strength (in terms of experience and company size), and portfolio specifications (in terms of number of services offered, number of analytical techniques used, types of glycans analyzed, types of analytes processed and applications).
  • Elaborate profiles of prominent service providers in this domain. Each company profile includes a brief overview of the company, its financial information (if available), information on service portfolio, recent developments, and an informed future outlook.
  • A detailed assessment of the current market landscape of surface glycan targeting therapeutics, providing information on the phase of development (commercial, clinical, preclinical, and discovery) of lead candidates, target disease indication and therapeutic area, type of drug molecule (antibody, antibody-drug conjugate, enzyme, glyco- conjugate vaccine and CAR- T cells), target glycan / glycoconjugate molecule, type of therapy (monotherapy, combination therapy and both), and technology platform used. In addition, it provides details on drug developer(s), including information on their year of establishment, company size, and location of headquarters.
  • A detailed analysis of grants that have been awarded to research institutes for surface glycan targeting therapeutic projects, during the period, 2016 and 2021, based on several relevant parameters, such as year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, study section involved, type of recipient organizations and focus area. In addition, it highlights geographical distribution of recipient organizations, popular funding institute centers, prominent program officers, and popular recipient organizations. 
  • An analysis of the partnerships that have been established in this domain since 2015, covering instances of acquisitions and mergers, licensing agreements, product development agreements, process development agreement, research agreements, and other relevant types of deals.
  • A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired during the time period between 2015- 2021, based on several relevant parameters, such as year of agreement, type of deal, geographical location of headquarters, company size, and the key value drivers. In addition, it represents an ownership change matrix, providing a summary of the involvement of private and public sector entities in this domain.
  • A case study on the potential clients of glycan analysis services providers; it presents a list of Fc glycoengineered antibody developers, along with information on their year of establishment, company size, and location of headquarters. In addition, it provides information on phase of development of the glycoengineered antibody, target disease indication, therapeutic area, type of molecule, its biological target, type of therapy, route of administration, impact of Fc engineering and technology platform used.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities of glycan analysis service providers. Based on various parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the glycoprotein therapeutics market, we have developed informed estimates on the evolution of the market for the period 2021-2030. Our year-wise projections of the current and forecasted opportunity have further been segmented across company size (small, mid-sized and large), analytical techniques used (spectroscopy, chromatography, microarrays and electrophoresis), key geographical locations (North America, Europe and Asia- Pacific). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were influenced by discussions held with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders:

  • Biswa Choudhury (Technical Director, GlycoAnalytics Core, University of California)
  • Erdmann Rapp (Founder and Chief Executive Officer, glyXera)
  • Juhani Saarinen (Chief Executive Officer, Glykos Finland)  

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading industry and non- industry players offering glycan analysis services?
  • Which are the key geographies where glycan analysis service providers are located?
  • What are the common analytical techniques used by the service providers?
  • What are the prevalent R&D trends related to surface glycan targeting therapies? 
  • Which surface glycan molecules are targeted by such therapies?
  • What are the key therapeutic areas for which such therapies are being / have been developed? 
  • Who are the leading players engaged in the development of surface glycan targeting therapies?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • What are the key value drivers of the merger and acquisition activity within this domain?
  • How is the current and future opportunity, related to glycan analysis services, likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high- level view on the likely evolution of the glycan analysis services market in the mid to long term.

Chapter 3 provides a general introduction to glycans and glycoconjugates, laying emphasis on the importance of glycosylation analysis in biopharmaceutical development and biomarker discovery. The chapter describes the methodologies used to analyze intact and released glycans, and the various reagents and analytical techniques that form the basis for such tests. In addition, the chapter highlights the key considerations for selecting a glycan analysis service provider, along with the benefits and risks associated with outsourcing glyco- analytical operations.

Chapter 4 provides an overview of the overall glycan analysis services landscape, including information related to over 130 industry and non-industry players offering contract services for glycan analysis.  It features an in- depth analysis of the industry players, based on a number of parameters, such as year of establishment, company size, geographical location of headquarters, type of service(s) offered (glycan profiling and heterogeneity analysis, glycosylation site mapping and occupancy analysis, site- specific glycosylation analysis, glycan structure analysis, monosaccharide quantification analysis and protein-  glycan binding analysis), type of glycoconjugate and glycan analyzed (N- glycan, O- glycan and glycolipid), type of sample analyzed (biotherapeutics and cellular), type of analyte processed (intact glycoprotein, glycopeptide, released glycan, monosaccharide and polysaccharide), type of analytical technique used (chromatography, spectroscopy, electrophoresis and microarray- based technique),application area (R&D / early-  stage drug development and in-  process drug development). The chapter also provides information on additional service(s) offered (peptide mapping, post- translational modification analysis, protein terminal sequencing and glycan / glycoconjugate synthesis), and availability of synthetic glycans and analytical kits / tests.  In addition, it includes an analysis of non- industry players based on the type of glycoanalytical service offered and analytical technique used by them.

Chapter 5 provides an insightful competitiveness analysis of the glycan analysis service providers based in North America, Europe and Asia-Pacific. The analysis compares the capabilities of companies on the basis of supplier strength (based on the year of establishment and size of the service provider) and service portfolio strength (in terms of number of services offered, number of analytical techniques used, types of glycans analyzed, types of analytes processed and number of applications).

Chapter 6 includes detailed profiles the key players that are active in this domain. Each company profile features a brief overview of the company, financial information (if available), information on service portfolio, recent developments and an informed future outlook.

Chapter 7 provides information on more than 80 development programs for surface glycan targeting therapeutics that are either approved or being developed across various phase of development (commercial, clinical, preclinical, and discovery) of lead candidates, target disease indication and therapeutic area, type of drug molecule (antibody, antibody- drug conjugate, enzyme, glyco- conjugate vaccine and CAR- T cells), target glycan / glycoconjugate molecule, type of therapy (monotherapy, combination therapy and both), and technology platform used. In addition, it provides details on drug developer(s), including information on their year of establishment, company size, and location of their headquarters.

Chapter 8 provides an analysis of the grants awarded to research institutes for the projects related to surface glycan therapeutics, during the period 2016 and 2021, based on several important parameters, such year of grant award, amount awarded, administering institute center, support period, type of grant application, purpose of grant award, activity code, focus area, study section involved, and type of recipient organizations. In addition, it highlights popular funding institute centers, prominent program officers, and popular recipient organizations.  

Chapter 9 features a discussion on the collaborations and partnerships that have been established in this domain since 2015. It includes a brief description of various types of partnership models (acquisitions and mergers, licensing agreements, product development agreements, process development agreements, research agreements, and other agreements) that have been adopted by stakeholders in this domain. In addition, it includes a detailed analysis of partnerships, based on year of partnership, type of partnership, and regional activity.

Chapter 10 presents insights from a detailed analysis of the mergers and acquisitions that have taken place in this domain, during the period 2015- 2021. It is worth mentioning that the data captured during our research was analyzed based on multiple parameters, such as year of agreement, type of deal, geographical location, size and ownership of the companies involved, and the key value drivers.

Chapter 11 presents a case study on the potential clients of glycan analysis services providers, featuring a list of Fc glycoengineered antibody developers, along with information on their year of establishment, company size, and location of headquarters. In addition, it provides information on phase of development of the glycoengineered antibody, target disease indication, therapeutic area, type of molecule, its biological target, type of therapy, route of administration, impact of Fc engineering and technology platform used.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of glycan analysis services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented across company size (small, mid- sized and large), analytical techniques used (spectroscopy, chromatography, microarrays and electrophoresis) and key geographical locations (North America, Europe and Asia- Pacific).  

Chapter 13 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Biswa Choudhury (Technical Director, GlycoAnalytics Core, University of California), Erdmann Rapp (Chief Executive Officer, glyXera) and Juhani Saarinen (Founder and Chief Executive Officer, Glykos Finland).  

Chapter 14 is a summary of the overall report. It presents a list of key takeaways and our independent opinions on the current market scenario.

Chapter 15 is an appendix that contains tabulated data and numbers for all the figures in the report.

Chapter 16 is an appendix that provides the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY
2.1. Chapter Overview

3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Glycans and Glycoconjugates
3.3. Glycosylation of Therapeutic Proteins

3.4. Overview of Protein Glycosylation Analysis (Glycan Analysis)
3.4.1. Methods Used in Glycan Analysis
3.4.2. Techniques Used for Glycan Analysis

3.5. Outsourcing Glycan Analysis
3.5.1. Need for Outsourcing
3.5.2. Advantages of Outsourcing
3.5.3. Guidelines for Selecting a Service Provider

3.6. Concluding Remarks

4. GLYCAN ANALYSIS SERVICE PROVIDERS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Glycan Analysis Service Providers: Overall Market Landscape
4.2.1. Glycan Analysis Service Providers: Industry Players
4.2.1.1. Analysis by Year of Establishment
4.2.1.2. Analysis by Company Size
4.2.1.3. Analysis by Location of Headquarters
4.2.1.4. Analysis by Availability of Contract Development and Manufacturing Capabilities
4.2.1.5. Analysis by Type of Service Offered
4.2.1.6. Analysis by Type of Glycoconjugate / Glycan Analyzed
4.2.1.7. Analysis by Type of Sample Processed
4.2.1.8. Analysis by Type of Analyte Processed
4.2.1.9. Analysis by Type of Analytical Technique Used
4.2.1.10. Analysis by Application Area
4.2.1.11. Analysis by Additional Services Offered
4.2.1.12. Analysis by Additional Products Offered

4.2.2. Glycan Analysis Service Providers: Non-Industry Players
4.2.2.1. Analysis by Service Location
4.2.2.2. Analysis by Type of Service Offered
4.2.2.3. Analysis by Type of Analytical Technique Used

5. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS
5.1. Chapter Overview
5.2. Methodology
5.3. Assumptions / Key Parameters
5.3.1. Competitiveness Analysis: Glycan Analysis Service Providers in North America
5.3.2. Competitiveness Analysis: Glycan Analysis Service Providers in Europe
5.3.3. Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
5.4. Summary of Key Players

6. GLYCAN ANALYSIS SERVICE PROVIDERS: COMPANY PROFILES
6.1. Chapter Overview
6.2. Glycan Analysis Service Providers: North America
6.2.1. CD BioGlyco
6.2.1.1. Company Overview
6.2.1.2. Service Portfolio
6.2.1.3. Recent Developments and Future Outlook

6.2.2. Creative Biolabs
6.2.2.1. Company Overview
6.2.2.2. Service Portfolio
6.2.2.3. Recent Developments and Future Outlook

6.2.3. Creative Proteomics
6.2.3.1. Company Overview
6.2.3.2. Service Portfolio
6.2.3.3. Recent Developments and Future Outlook

6.2.4. Thermo Fisher Scientific
6.2.4.1. Company Overview
6.2.4.2. Financial Information
6.2.4.3. Service Portfolio
6.2.4.4. Recent Developments and Future Outlook

6.3. Glycan Analysis Service Providers: Europe
6.3.1. Glykos Finland
6.3.1.1. Company Overview
6.3.1.2. Service Portfolio
6.3.1.3. Recent Developments and Future Outlook

6.3.2. glyXera
6.3.2.1. Company Overview
6.3.2.2. Service Portfolio
6.3.2.3. Recent Developments and Future Outlook

6.3.3. Ludger
6.3.3.1. Company Overview
6.3.3.2. Service Portfolio
6.3.3.3. Recent Developments and Future Outlook

6.3.4. Protagen Protein Services
6.3.4.1. Company Overview
6.3.4.2. Service Portfolio
6.3.4.3. Recent Developments and Future Outlook

6.4. Glycan Analysis Service Providers: Asia-Pacific and rest of the world
6.4.1. Mithra Biotechnology
6.4.1.1. Company Overview
6.4.1.2. Service Portfolio
6.4.1.3. Recent Developments and Future Outlook

6.4.2. Protein Works
6.4.2.1. Company Overview
6.4.2.2. Service Portfolio
6.4.2.3. Recent Developments and Future Outlook

6.4.3. Savyon Diagnostics
6.4.3.1. Company Overview
6.4.3.2. Service Portfolio
6.4.3.3. Recent Developments and Future Outlook

6.4.4. Syngene
6.4.4.1. Company Overview
6.4.4.2. Financial Information
6.4.4.3. Service Portfolio
6.4.4.4. Recent Developments and Future Outlook

7. SURFACE GLYCAN TARGETING THERAPEUTICS: OVERALL MARKET LANDSCAPE
7.1. Chapter Overview
7.2. Surface Glycan Targeting Therapeutics: Pipeline Review
7.2.1. Analysis by Phase of Development
7.2.2. Analysis by Target Disease Indication and Therapeutic Area
7.2.3. Analysis by Type of Drug Molecule
7.2.4. Analysis by Phase of Development and Therapeutic Area
7.2.5. Analysis by Type of Drug Molecule and Therapeutic Area
7.2.6. Analysis by Target Glycoconjugate and Glycan Molecule
7.2.7. Analysis by Type of Therapy
7.2.8. Popular Technology Platforms: Distribution by Number of Products

7.3. Surface Glycan Targeting Therapeutics: List of Developers
7.3.1. Analysis by Type of Player
7.3.2. Analysis by Year of Establishment
7.3.3. Analysis by Company Size
7.3.4. Analysis by Location of Headquarters
7.3.5. Leading Players: Analysis by Number of Products
7.4. Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Product’s Stage of Development

8. SURFACE GLYCAN TARGETING THERAPEUTICS: ACADEMIC GRANTS ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Surface Glycan Targeting Therapeutics: Academic Grants Analysis
8.3.1. Analysis by Year of Grant Award
8.3.2. Analysis by Amount Awarded
8.3.3. Analysis by Administering Institute Center
8.3.4. Analysis by Support Period
8.3.5. Analysis by Administering Institute Center and Support Period
8.3.6. Analysis by Type of Grant Application
8.3.7. Analysis by Purpose of Grant Award
8.3.8. Analysis by Activity Code
8.3.9. Word Cloud Analysis: Emerging Focus Areas
8.3.10. Analysis by Study Section Involved
8.3.11. Popular NIH Departments: Analysis by Number of Grants
8.3.12. Analysis by Type of Recipient Organization
8.3.13. Prominent Program Officers: Analysis by Number of Grants
8.3.14. Popular Recipient Organizations: Analysis by Number of Grants
8.3.15. Regional Distribution of Recipient Organizations

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. List of Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year of Partnership and Type of Partner
9.3.4. Analysis by Type of Partnership and Type of Partner
9.3.5. Analysis by Year of Partnership and Type of Parent Company
9.3.6. Analysis by Type of Partnership and Type of Parent Company
9.3.7. Most Active Players: Analysis by Number of Partnerships
9.3.8. Regional Analysis
9.3.9. Intercontinental and Intracontinental Agreements
9.3.10. Analysis by Therapeutic Area

10. MERGERS AND ACQUISITONS
10.1. Chapter Overview
10.2. Merger and Acquisition Models
10.3. List of Mergers and Acquisitions
10.3.1. Analysis by Type of Deal
10.3.2. Analysis by Year of Deal
10.3.3. Analysis by Geography
10.3.4. Intercontinental and Intracontinental Deals
10.3.5. Analysis by Company Size
10.3.6. Ownership Change Matrix
10.3.7. Key Players: Analysis by Number of Mergers and Acquisitions
10.3.8. Analysis by Key Value Drivers

11. CASE STUDY ON POTENTIAL CLIENTS OF GLYCAN ANALYSIS SERVICE PROVIDERS
11.1. Chapter Overview
11.2. List of Fc Glycoengineered Antibody Developers
11.2.1. Analysis by Year of Establishment
11.2.2. Analysis by Company Size
11.2.3. Analysis by Location of Headquarters
11.2.4. Leading Players: Analysis by Number of Products

11.3. Fc Glycoengineered Antibody Therapeutics: Pipeline Review
11.3.1. Analysis by Phase of Development
11.3.2. Analysis by Target Disease Indication
11.3.3. Analysis by Therapeutic Area
11.3.4. Analysis by Type of Antibody
11.3.5. Analysis by Type of Biological Target
11.3.6. Analysis by Type of Therapy
11.3.7. Analysis by Route of Administration
11.3.8. Analysis by Impact of Fc Engineering
11.3.9. Analysis by Technology Platform Used

12. GLYCAN ANALYSIS SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Glycan Analysis Services Market, 2021-2030
12.4. Global Glycan Analysis Services Market, 2021-2030: Distribution by Company Size
12.4.1. Glycan Analysis Services Market for Small Companies, 2021-2030
12.4.2. Glycan Analysis Services Market for Mid-sized Companies, 2021-2030
12.4.3. Glycan Analysis Services Market for Large Companies, 2021-2030
12.5. Global Glycan Analysis Services Market, Distribution by Type of Analytical Technique, 2021-2030
12.5.1. Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030
12.5.2. Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030
12.5.3. Glycan Analysis Services Market for Microarray-based Techniques, 2021-2030
12.5.4. Glycan Analysis Services Market for Electrophoresis-based Techniques, 2021-2030

12.6. Global Glycan Analysis Services Market, 2021-2030: Distribution by Geography
12.6.1 Glycan Analysis Services Market in the US, 2021-2030
12.6.2 Glycan Analysis Services Market in Canada, 2021-2030
12.6.3 Glycan Analysis Services Market in the UK, 2021-2030
12.6.4 Glycan Analysis Services Market in France, 2021-2030
12.6.5 Glycan Analysis Services Market in Germany, 2021-2030
12.6.6 Glycan Analysis Services Market in Spain, 2021-2030
12.6.7 Glycan Analysis Services Market in Italy, 2021-2030
12.6.8 Glycan Analysis Services Market in Rest of Europe, 2021-2030
12.6.9 Glycan Analysis Services Market in China, 2021-2030
12.6.10 Glycan Analysis Services Market in Japan, 2021-2030
12.6.11 Glycan Analysis Services Market in India, 2021-2030
12.6.12 Glycan Analysis Services Market in Asia-Pacific and rest of the world, 2021-2030

13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. GlycoAnalytics Core, University of California
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Biswa Choudhury, Technical Director

13.2. glyXera
13.2.1. Company / Organization Overview
13.2.2. Interview Transcript: Erdmann Rapp, Founder and Chief Executive Officer

13.3. Glykos Finland
13.3.1. Company / Organization Overview
13.3.2. Interview Transcript: Juhani Saarinen, Chief Executive Officer

14. CONCLUDING REMARKS
14.1. Chapter Overview

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 3.1 Immunoregulatory Roles of Antibody Glycosylation
Figure 3.2 Methods used in Glycan Analysis
Figure 3.3 Risks Associated with Outsourcing Glycan Analysis
Figure 3.4 Guidelines for Selecting a Glycan Analysis Service Provider
Figure 4.1 Glycan Analysis Service Providers: Overall Market Landscape
Figure 4.2 Glycan Analysis Service Providers (Industry Players): Distribution by Year of Establishment
Figure 4.3 Glycan Analysis Service Providers (Industry Players): Distribution by Company Size
Figure 4.4 Glycan Analysis Service Providers (Industry Players): Distribution by Location of Headquarters
Figure 4.5 World Map Representation: Analysis by Geography
Figure 4.6 Glycan Analysis Service Providers (Industry Players): Distribution by Availability of Contract Development and Manufacturing Capabilities
Figure 4.7 Glycan Analysis Service Providers (Industry Players): Distribution by Types of Services Offered
Figure 4.8 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Glycoconjugate(s) / Glycan(s) Analyzed
Figure 4.9 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Sample(s) Processed
Figure 4.10 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analyte(s) Processed
Figure 4.11 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analytical Technique(s) Used
Figure 4.12 Glycan Analysis Service Providers (Industry Players): Distribution by Application Area(s)
Figure 4.13 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Services Offered
Figure 4.14 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Products Offered
Figure 4.15 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Service Location
Figure 4.16 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Service(s) Offered
Figure 4.17 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Analytical Technique(s) Used
Figure 5.1 Competitiveness Analysis: Glycan Analysis Service Providers in North America
Figure 5.2 Competitiveness Analysis: Glycan Analysis Service Providers in Europe
Figure 5.3 Competitiveness Analysis: Glycan Analysis Service Providers in Asia-Pacific and rest of the world
Figure 5.4 Competitiveness Analysis of Glycan Analysis Service Providers: Competitiveness Score of Top Service Providers
Figure 6.1 Thermo Fisher Scientific: Annual Revenues, FY 2016-Q1 2021 (USD Billion)
Figure 6.2 Syngene: Annual Revenues, FY 2016-FY 2021 (INR Million)
Figure 7.1 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development
Figure 7.2 Surface Glycan Targeting Therapeutics: Distribution by Target Disease Indication and Therapeutic Area
Figure 7.3 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule
Figure 7.4 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development and Therapeutic Area
Figure 7.5 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule and Therapeutic Area
Figure 7.6 Surface Glycan Targeting Therapeutics: Distribution by Target Glycoconjugate and Glycan Molecule
Figure 7.7 Surface Glycan Targeting Therapeutics: Distribution by Type of Therapy
Figure 7.8 Popular Technology Platforms: Distribution by Number of Products
Figure 7.9 Surface Glycan Targeting Therapy Developers: Distribution by Type of Player
Figure 7.10 Surface Glycan Targeting Therapy Developers: Distribution by Year of Establishment
Figure 7.11 Surface Glycan Targeting Therapy Developers: Distribution by Company Size
Figure 7.12 Surface Glycan Targeting Therapy Developers: Distribution by Location of Headquarters
Figure 7.13 World Map Representation: Analysis by Geography
Figure 7.14 Leading Players: Distribution by Number of Products
Figure 7.15 Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Products’ Stage of Development
Figure 8.1 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2021 (till March)
Figure 8.2 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2016-2021 (till March)
Figure 8.3 Grant Analysis: Distribution by Administering Institute Center
Figure 8.4 Grant Analysis: Distribution by Support Period
Figure 8.5 Grant Analysis: Distribution by Administering Institute Center and Support Period
Figure 8.6 Grant Analysis: Distribution by Type of Grant Application
Figure 8.7 Grant Analysis: Distribution by Purpose of Grant Award
Figure 8.8 Grant Analysis: Distribution by Activity Code
Figure 8.9 Word Cloud: Emerging Focus Areas
Figure 8.10 Grant Analysis: Distribution by Study Section Involved
Figure 8.11 Popular NIH Departments: Distribution by Number of Grants
Figure 8.12 Grant Analysis: Distribution by Type of Recipient Organization
Figure 8.13 Most Prominent Program Officers: Distribution by Number of Grants
Figure 8.14 Popular Recipient Organizations: Distribution by Number of Grants
Figure 8.15 Grant Analysis: Regional Distribution of Recipient Organization
Figure 9.1 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2021 (till March)
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2021 (till March)
Figure 9.4 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 9.5 Most Active Players: Distribution by Number of Partnerships
Figure 9.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Parent Company
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Parent Company
Figure 9.8 Most Active Players: Distribution by Number of Partnerships
Figure 9.9 Partnerships and Collaborations: Regional Distribution
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.11 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.1 Mergers and Acquisitions: Distribution by Type of Deal
Figure 10.2 Mergers and Acquisitions: Cumulative Year-Wise Distribution, 2015- 2021 (till March)
Figure 10.3 Mergers and Acquisitions: Distribution by Geography
Figure 10.4 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
Figure 10.5 Mergers and Acquisitions: Company Logo Landscape
Figure 10.6 Acquisitions: Distribution by Company Size
Figure 10.7 Acquisitions: Ownership Change Matrix
Figure 10.8 Mergers and Acquisitions: Key Players
Figure 10.9 Mergers and Acquisitions: Key Value Drivers
Figure 11.1 Fc Glycoengineered Antibody Developers: Distribution by Year of Establishment
Figure 11.2 Fc Glycoengineered Antibody Developers: Distribution by Company Size
Figure 11.3 Fc Glycoengineered Antibody Developers: Distribution by Location of Headquarters
Figure 11.4 Leading Players: Distribution by Number of Products
Figure 11.5 Fc Glycoengineered Antibodies: Distribution by Phase of Development
Figure 11.6 Fc Glycoengineered Antibodies: Distribution by Target Disease Indication
Figure 11.7 Fc Glycoengineered Antibodies: Distribution by Therapeutic Area
Figure 11.8 Fc Glycoengineered Antibodies: Distribution by Type of Antibody
Figure 11.9 Fc Glycoengineered Antibodies: Distribution by Type of Biological Target
Figure 11.10 Fc Glycoengineered Antibodies: Distribution by Type of Therapy
Figure 11.11 Fc Glycoengineered Antibodies: Distribution by Route of Administration
Figure 11.12 Fc Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
Figure 11.13 Fc Glycoengineered Antibodies: Distribution by Technology Platform Used
Figure 12.1 Global Glycan Analysis Services Market, 2021-2030 (USD Million)
Figure 12.2 Global Glycan Analysis Services Market: Distribution by Company Size, 2021 and 2030: Base Scenario (USD Million)
Figure 12.3 Glycan Analysis Services Market for Small Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.4 Glycan Analysis Services Market for Mid-sized Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.5 Glycan Analysis Services Market for Large Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.6 Global Glycan Analysis Services Market: Distribution by Type of Analytical Technique (USD Million), 2021 and 2030
Figure 12.7 Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.8 Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.9 Glycan Analysis Services Market for Microarray- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.10 Glycan Analysis Market for Electrophoresis- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.11 Global Glycan Analysis Services Market: Distribution by Geography (USD Million), 2021 and 2030
Figure 12.12 Glycan Analysis Services Market in the US, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.13 Glycan Analysis Services Market in Canada, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.14 Glycan Analysis Services Market in the UK, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.15 Glycan Analysis Services Market in France, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.16 Glycan Analysis Services Market in the Germany, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.17 Glycan Analysis Services Market in Spain, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.18 Glycan Analysis Services Market in Italy, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.19 Glycan Analysis Services Market in Rest of Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.20 Glycan Analysis Services Market in China, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.21 Glycan Analysis Services Market in Japan, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.22 Glycan Analysis Services Market in India, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 12.23 Glycan Analysis Services Market in Other Asian Countries and Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 14.1 Concluding Remarks: Overall Market Landscape of Glycosylation Analysis Service Providers
Figure 14.2 Concluding Remarks: Overall Market Landscape of Surface Glycan Targeting Therapeutics and Therapy Developers
Figure 14.3 Concluding Remarks: Academic Grants Analysis
Figure 14.4 Concluding Remarks: Partnerships and Collaborations
Figure 14.5 Concluding Remarks: Mergers and Acquisitions
Figure 14.6 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Glycan Analysis: Glycan Sample Preparation Methods
Table 3.2 Glycan Analysis: Glycan Separation Methods
Table 3.3 Glycan Analysis: Glycan Detection Methods
Table 4.1 Glycan Analysis Service Providers: List of Industry Players
Table 4.2 Glycan Analysis Service Providers (Industry Players): Information on Type of Service(s) Offered
Table 4.3 Glycan Analysis Service Providers (Industry Players): Information on Type of Glycoconjugate(s) and Sample(s) Analyzed
Table 4.4 Glycan Analysis Service Providers (Industry Players): Information on Type of Analyte(s) Processed
Table 4.5 Glycan Analysis Service Providers (Industry Players): Information on Type of Analytical Technique(s) Used
Table 4.6 Glycan Analysis Service Providers (Industry Players): Information on Application Area(s) and Additional Service(s) Offered
Table 4.7 Glycan Analysis Service Providers: List of Non-Industry Players
Table 4.8 Glycan Analysis Service Providers (Non-Industry Players): Information on Type of Analytical Technique(s) Used
Table 6.1 Glycan Analysis Service Providers: List of Profiled Companies
Table 6.2 CD BioGlyco: Company Snapshot
Table 6.3 CD BioGlyco: Service Portfolio
Table 6.4 CD BioGlyco: Recent Developments and Future Outlook
Table 6.5 Creative Biolabs: Company Snapshot
Table 6.6 Creative Biolabs: Service Portfolio
Table 6.7 Creative Biolabs: Recent Developments and Future Outlook
Table 6.8 Creative Proteomics: Company Snapshot
Table 6.9 Creative Proteomics: Service Portfolio
Table 6.10 Creative Proteomics: Recent Developments and Future Outlook
Table 6.11 Thermo Fisher Scientific: Company Snapshot
Table 6.12 Thermo Fisher Scientific: Service Portfolio
Table 6.13 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 6.14 Glykos Finland: Company Snapshot
Table 6.15 Glykos Finland: Service Portfolio
Table 6.16 Glykos Finland: Recent Developments and Future Outlook
Table 6.17 glyXera: Company Snapshot
Table 6.18 glyXera: Service Portfolio
Table 6.19 glyXera: Recent Developments and Future Outlook
Table 6.20 Ludger: Company Snapshot
Table 6.21 Ludger: Service Portfolio
Table 6.22 Ludger: Recent Developments and Future Outlook
Table 6.23 Protagen Protein Services: Company Snapshot
Table 6.24 Protagen Protein Services: Service Portfolio
Table 6.25 Protagen Protein Services: Recent Developments and Future Outlook
Table 6.26 Mithra Biotechnology: Company Snapshot
Table 6.27 Mithra Biotechnology: Service Portfolio
Table 6.28 Mithra Biotechnology: Recent Developments and Future Outlook
Table 6.29 Protein Works: Company Snapshot
Table 6.30 Protein Works: Service Portfolio
Table 6.31 Protein Works: Recent Developments and Future Outlook
Table 6.32 Savyon Diagnostics: Company Snapshot
Table 6.33 Savyon Diagnostics: Service Portfolio
Table 6.34 Savyon Diagnostics: Recent Developments and Future Outlook
Table 6.35 Syngene: Company Snapshot
Table 6.36 Syngene: Service Portfolio
Table 6.37 Syngene: Recent Developments and Future Outlook
Table 7.1 Surface Glycan Targeting Therapeutics: Information on Phase of Development, Target Disease Indication and Type of Drug Molecule
Table 7.2 Surface Glycan Targeting Therapeutics: Information on Target Glycan / Glycoconjugate Molecule, Type of Therapy and Technology Platforms
Table 7.3 Surface Glycan Targeting Therapeutics: List of Developers
Table 9.1 List of Partnerships and Collaborations, 2015-2021 (till March)
Table 10.1 List of Mergers and Acquisitions, 2015-2021 (till March)
Table 11.1 Fc Glycoengineered Antibodies: List of Developers
Table 11.2 Fc Glycoengineered Antibodies: List of Drugs
Table 13.1 GlycoAnalytics Core, University of California: Key Highlights
Table 15.1 Glycan Analysis Service Providers: Overall Market Landscape
Table 15.2 Glycan Analysis Service Providers (Industry Players): Distribution by Year of Establishment
Table 15.3 Glycan Analysis Service Providers (Industry Players): Distribution by Company Size
Table 15.4 Glycan Analysis Service Providers (Industry Players): Distribution by Location of Headquarters
Table 15.5 World Map Representation: Distribution by Geography
Table 15.6 Glycan Analysis Service Providers (Industry Players): Distribution by Availability of Contract Development and Manufacturing Capabilities
Table 15.7 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Service(s) Offered
Table 15.8 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Glycoconjugate(s) and Glycan(s) Analyzed
Table 15.9 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Sample(s) Analyzed
Table 15.10 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analyte(s) Processed
Table 15.11 Glycan Analysis Service Providers (Industry Players): Distribution by Type of Analytical Technique(s) Used
Table 15.12 Glycan Analysis Service Providers (Industry Players): Distribution by Application Area(s)
Table 15.13 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Service(s) Offered
Table 15.14 Glycan Analysis Service Providers (Industry Players): Distribution by Additional Product(s) Offered
Table 15.15 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Service Location
Table 15.16 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Service(s) Offered
Table 15.17 Glycan Analysis Service Providers (Non-Industry Players): Distribution by Type of Analytical Technique(s) Used
Table 15.18 Thermo Fisher Scientific: Annual Revenues, FY 2016-Q1 2021 (USD Billion)
Table 15.19 Syngene: Annual Revenues, FY 2016-FY 2021 (INR Million)
Table 15.20 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development
Table 15.21 Surface Glycan Targeting Therapeutics: Distribution by Target Disease Indication and Therapeutic Area
Table 15.22 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule
Table 15.23 Surface Glycan Targeting Therapeutics: Distribution by Phase of Development and Therapeutic Area
Table 15.24 Surface Glycan Targeting Therapeutics: Distribution by Type of Drug Molecule and Therapeutic Area
Table 15.25 Surface Glycan Targeting Therapeutics: Distribution by Target Glycan / Glycoconjugate Molecule
Table 15.26 Surface Glycan Targeting Therapeutics: Distribution by Type of Therapy
Table 15.27 Popular Technology Platforms: Distribution by Number of Products
Table 15.28 Surface Glycan Targeting Therapy Developers: Distribution by Type of Player
Table 15.29 Surface Glycan Targeting Therapy Developers: Distribution by Year of Establishment
Table 15.30 Surface Glycan Targeting Therapy Developers: Distribution by Company Size
Table 15.31 Surface Glycan Targeting Therapy Developers: Distribution by Location of Headquarters
Table 15.32 World Map Representation: Analysis by Geography
Table 15.33 Leading Developers: Distribution by Number of Products
Table 15.34 Heat Map Analysis: Distribution by Company Size, Location of Headquarters and Products’ Stage of Development
Table 15.35 Grant Analysis: Cumulative Trend by Year of Grant Award, 2016-2021 (till March)
Table 15.36 Grant Analysis: Cumulative Distribution by Amount Awarded (USD Million), 2016-2021 (till March)
Table 15.37 Grant Analysis: Distribution by Administering Institute Center
Table 15.38 Grant Analysis: Distribution by Support Period
Table 15.39 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 15.40 Grant Analysis: Distribution by Type of Grant Application
Table 15.41 Grant Analysis: Distribution by Purpose of Grant Award
Table 15.42 Grant Analysis: Distribution by Activity Code
Table 15.43 Grant Analysis: Distribution by Study Section Involved
Table 15.44 Popular NIH Departments: Distribution by Number of Grants
Table 15.45 Grant Analysis: Distribution by Types of Recipient Organizations
Table 15.46 Most Prominent Program Officers: Distribution by Number of Grants
Table 15.47 Popular Recipient Organization: Distribution by Number of Grants
Table 15.48 Grant Analysis: Regional Distribution of Recipient Organizations
Table 15.49 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2021 (till March)
Table 15.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.51 Partnerships and Collaborations: Distribution by Year and Type of Partnership, 2015-2021 (till March)
Table 15.52 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 15.53 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 15.54 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Parent Company
Table 15.55 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Parent Company
Table 15.56 Most Active Players: Distribution by Number of Partnerships
Table 15.57 Partnerships and Collaborations: Regional Distribution
Table 15.58 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 15.59 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 15.60 Mergers and Acquisitions: Distribution by Type of Deal
Table 15.61 Mergers and Acquisitions: Cumulative Year-Wise Distribution, 2015-2021 (till March)
Table 15.62 Mergers and Acquisitions: Distribution by Geography
Table 15.63 Mergers and Acquisitions: Intercontinental and Intracontinental Distribution
Table 15.64 Acquisitions: Distribution by Company Size
Table 15.65 Acquisitions: Ownership Change Matrix
Table 15.66 Mergers and Acquisitions: Key Players
Table 15.67 Mergers and Acquisitions: Key Value Drivers
Table 15.68 Fc Glycoengineered Antibody Product Developers: Distribution by Year of Establishment
Table 15.69 Fc Glycoengineered Antibody Product Developers: Distribution by Company Size
Table 15.70 Fc Glycoengineered Antibody Product Developers: Distribution by Location of Headquarters
Table 15.71 Leading Players: Distribution by Number of Products
Table 15.72 Fc Glycoengineered Antibodies: Distribution by Phase of Development
Table 15.73 Fc Glycoengineered Antibodies: Distribution by Target Disease Indication
Table 15.74 Fc Glycoengineered Antibodies: Distribution by Therapeutic Area
Table 15.75 Fc Glycoengineered Antibodies: Distribution by Type of Antibody
Table 15.76 Fc Glycoengineered Antibodies: Distribution by Biological Target
Table 15.77 Fc Glycoengineered Antibodies: Distribution by Type of Therapy
Table 15.78 Fc Glycoengineered Antibodies: Distribution by Route of Administration
Table 15.79 Fc Glycoengineered Antibodies: Distribution by Impact of Fc Engineering
Table 15.80 Fc Glycoengineered Antibodies: Distribution by Technology Platform Used
Table 15.81 Global Glycan Analysis Services Market, 2021-2030 (USD Million)
Table 15.82 Global Glycan Analysis Services Market: Distribution by Company Size, 2021 and 2030: Base Scenario (USD Million)
Table 15.83 Glycan Analysis Services Market for Small Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.84 Glycan Analysis Services Market for Mid-sized Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.85 Glycan Analysis Services Market for Large Companies, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.86 Global Glycan Analysis Services Market: Distribution by Type of Analytical Technique (USD Million), 2021 and 2030
Table 15.87 Glycan Analysis Services Market for Spectroscopy-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.88 Glycan Analysis Services Market for Chromatography-based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.89 Glycan Analysis Services Market for Microarray- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.90 Glycan Analysis Market for Electrophoresis- based Techniques, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.91 Global Glycan Analysis Services Market: Distribution by Geography (USD Million), 2021 and 2030
Table 15.92 Glycan Analysis Services Market in the US, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.93 Glycan Analysis Services Market in Canada, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.94 Glycan Analysis Services Market in the UK, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.95 Glycan Analysis Services Market in France, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.96 Glycan Analysis Services Market in the Germany, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.97 Glycan Analysis Services Market in Spain, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.98 Glycan Analysis Services Market in Italy, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.99 Glycan Analysis Services Market in Rest of Europe, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.100 Glycan Analysis Services Market in China, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.101 Glycan Analysis Services Market in Japan, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.102 Glycan Analysis Services Market in India, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.103 Glycan Analysis Services Market in Other Asian Countries and Rest of the World, 2021-2030: Conservative, Base and Optimistic Scenarios (USD Million)

List of Companies

The following companies and organizations are mentioned in the report.

  1. 10x Genomics
  2. A*STAR Bioprocessing Technology Institute (BTI)
  3. Abzena
  4. Academia Sinica
  5. AddLife
  6. Admescope (Acquired by Symerers)
  7. Advantar Laboratories (Acquired by Eurofins Scientific) 
  8. AGC Biologics
  9. Agency for Science, Technology and Research (A*STAR)
  10. Agilent Technologies
  11. Airway Therapeutics
  12. Ajinomoto Althea
  13. Ajinomoto Bio-Pharma Services
  14. Alcami
  15. Allergan Biologics
  16. Alliance Protein Laboratories (Acquired by KBI Biopharma)
  17. Almac
  18. Alphalyse
  19. Alvotech
  20. Amgen
  21. ams Laboratories (Acquired by Eurofins Scientific) 
  22. Amthera
  23. Analytical Instrumentation Core, Boston University School of Medicine
  24. Ansun Biopharma (formerly NexBio)
  25. Applied Process Company (APC)
  26. Applied Pharmaceutical Innovation (API)
  27. Aragen Bioscience
  28. Argenx
  29. Asparia Glycomics
  30. AstraZeneca
  31. Australian Proteome Analysis Facility (APAF), Macquarie University
  32. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  33. Avomeen (Acquired by Element Materials Technology)
  34. Baylor College of Medicine
  35. Be The Match BioTherapies
  36. Beroni Group
  37. BioAnalytix (Acquired by Protagen Protein Services)
  38. Biofidus
  39. Biogen
  40. Biomedica (Acquired by AddLife)
  41. Biomedical FT-ICR Mass Spectrometry Laboratory, University of Alabama at Birmingham
  42. Biomeva (Acquired by AGC)
  43. BioMS
  44. BioNTech
  45. BioPharmaSpec
  46. BioReliance
  47. BiosanaPharma
  48. Bio-Shape
  49. Biosilu Healthcare
  50. Boehringer Ingelheim
  51. BRI Biopharmaceutical Research (Acquired by Frontage Laboratories)
  52. Cambridge Biologics
  53. Canadian Glycomics Network (GlycoNet)
  54. Cantargia
  55. CD BioGlyco
  56. CD Genomics
  57. Cell Signaling Technology (CST)
  58. CellmAbs
  59. Celonic
  60. Centre for Cellular and Molecular Platforms (C-CAMP)
  61. Centre for Process Innovation (CPI)
  62. Centre for the AIDS Programme of Research in South Africa (CAPRISA)
  63. Charles River Laboratories
  64. Chembind
  65. Chemily Glycoscience
  66. Chemistry Research Laboratory, University of Oxford
  67. China Biotech Services (formerly Rui Kang Pharmaceutical Group Investments)
  68. CHO Pharma
  69. Chromous Biotech
  70. CMC Biologics (Acquired by AGC)
  71. Cobra Biologics (Acquired by Cognate BioServices)
  72. Cognate BioServices (Acquired by Charles River Laboratories)
  73. Complex Carbohydrate Research Center (CCRC), University of Georgia
  74. Cornerstone Analytical Laboratories (CAL)
  75. Consortium de recherche biopharmaceutique (CQDM)
  76. Creative Biolabs
  77. Creative Proteomics
  78. Croatian Agency for SMEs, Innovations and Investments (HAMAG-BICRO)
  79. Current Medical Information Center (CMIC)
  80. Cytiva (formerly GE Healthcare Life Sciences)
  81. Cytovance Biologics (Acquired by Hepalink USA)
  82. Daiichi Sankyo
  83. Danaher
  84. DCPrime
  85. Delenex Therapeutics (Acquired by Kuur Therapeutics)
  86. Department of Biology, University of York
  87. Development Center for Biotechnology (DCB)
  88. Dextra Laboratories
  89. Diteba
  90. DNA Xperts
  91. EirGenix
  92. Element Materials Technology
  93. Elicityl
  94. Elion Labs (Acquired by KBI Biopharma) 
  95. Elpiscience
  96. Emory Comprehensive Glycomics Core (ECGC), Emory University School of Medicine
  97. Eurofins BioPharma Product Testing
  98. Eurofins DiscoverX
  99. Eurofins Scientific 
  100. Ferrier Research Institute, Victoria University of Wellington
  101. ForteBio Pall Life Science
  102. Frontage Laboratories
  103. Functional Genomics Center Zurich
  104. Gemini Biosciences
  105. Genentech
  106. Genos Glyco
  107. Genovis
  108. GenScript ProBio
  109. GeoVax
  110. Gilead Sciences 
  111. GlaxoSmithKline
  112. Glycan Therapeutics
  113. GLYcoDiag
  114. GlycoDisplay
  115. GlycoEra
  116. Glycomics Core, Beth Israel Deaconess Medical Center (BIDMC)
  117. GlycoMScan
  118. GlycoNex
  119. Glycosciences Laboratory, Imperial College London
  120. GlycoScreen
  121. GlycoSeLect
  122. GlycoTechnica
  123. GlycoThera (Acquired by Alvotech) 
  124. Glycotope
  125. Glycovax Pharma
  126. Glyde Bio
  127. GlykoGen
  128. Glykos Finland
  129. GlyTR Therapeutics
  130. glyXera
  131. GO Therapeutics
  132. Goodwin Biotechnology
  133. GP BioSciences
  134. Helmholtz-Zentrum Dresden-Rossendorf (HZDR)
  135. Helsinki Institute of Life Science (HiLIFE)
  136. Hepalink USA (subsidiary of Shenzhen Hepalink Pharmaceutical)
  137. HJB
  138. Horizon Therapeutics
  139. Humanigen
  140. Icahn School of Medicine at Mount Sinai
  141. InnoMol
  142. Innovation Network Corporation of Japan (INCJ)
  143. Institute for Glycomics, Griffith University
  144. Institute of Chemistry, Slovak Academy of Sciences
  145. International AIDS Vaccine Initiative (IAVI)
  146. Intertek
  147. Iovance Biotherapeutics
  148. JSR Life Sciences
  149. KBI Biopharma (Acquired by JSR)
  150. King’s College London
  151. Kuur Therapeutics (formerly Cell Medica)
  152. Kymos Pharma Services
  153. Kyowa Hakko Kirin
  154. LakePharma
  155. Lebrilla League
  156. Leo Pharma
  157. Livogen Pharmed
  158. Ludger
  159. MabSpace Biosciences (Acquired by HJB)
  160. MabVax Therapeutics (Acquired by BioNTech)
  161. Madison Dearborn Partners (MDP)
  162. Max Planck Institute of Colloids and Interfaces (MPICI)
  163. McMaster University
  164. Medicinal Chemistry Pharmaceutical
  165. Menarini
  166. Meridian Biopharmaceuticals
  167. Mithra Biotechnology
  168. MOBILion Systems
  169. Monash Proteomics & Metabolomics Facility (MPMF), Monash University
  170. MS Bioworks
  171. MtoZ Biolabs
  172. National Cancer Institute
  173. National Centre for Biological Sciences (NCBS), Tata Institute of Fundamental Research
  174. National Heart, Lung, and Blood Institute
  175. National Institute for Bioprocessing Research & Training (NIBRT)
  176. National Institute of Allergy and Infectious Diseases (NIAID)
  177. New England Biolabs (NEB)
  178. Nitto Avecia Pharma Services
  179. Northwestern University
  180. Novatia
  181. OBI Pharma 
  182. Octapharma
  183. OmniChem (Acquired by Ajinomoto Althea)
  184. OncoCare Therapeutics
  185. Oncora Medical
  186. OncoVent
  187. ONK Therapeutics
  188. Oragenics
  189. Otsuka Pharmaceutical
  190. Pace Analytical Life Sciences
  191. Pacific BioLabs
  192. PAIA Biotech
  193. Palleon Pharmaceuticals
  194. Paradigm Biopharmaceuticals
  195. Paraná's Institute of Technology (TECPAR)
  196. Pfizer
  197. Pharmaprogress (Acquired by KYMOS)
  198. PhAST (Acquired by Eurofins BioPharma Product Testing)
  199. Pneumagen
  200. Poochon Scientific
  201. Portuguese Oncology Institute of Porto (IPO Porto)
  202. Profacgen
  203. ProGlycAn, University of Natural Resources and Life Sciences Vienna (BOKU)
  204. Prolytic (Acquired by KYMOS)
  205. Protagen Protein Services
  206. Protein Works
  207. Proteodynamics
  208. ProteomeTech
  209. Proteomics Core Facility (PCF), University of Gothenberg
  210. Proteomics International
  211. ProtTech
  212. ProZyme (Acquired by Agilent Technologies)
  213. Quality Assistance
  214. Quantum Hi-Tech (China) Biological (Acquired by Shanghai ChemPartner)
  215. Quest PharmaTech
  216. Reading Scientific Services
  217. Realist Pharma 
  218. Recepta Biopharma
  219. Recombio 
  220. Research Triangle Institute (RTI)
  221. RMI Laboratories (Acquired by Frontage Laboratories)
  222. Roche
  223. Rockefeller University
  224. Samsung BioLogics
  225. Sandor LifeSciences
  226. Sanofi
  227. Sartorius Stedim Biotech
  228. Savyon Diagnostics
  229. Scancell
  230. School of Biological and Chemical Sciences, Queen Mary University of London
  231. SCIEX
  232. Scripps Research
  233. Seagen
  234. SGS
  235. Shanghai Applied Protein Technology
  236. Shanghai ChemPartner
  237. Shantani Proteome Analytics
  238. Siamab Therapeutics
  239. Sienna Cancer Diagnostics (Acquired by Bard1 Life Sciences)
  240. Sinensis Life Sciences (Acquired by Eurofins Scientific)
  241. Sinobioway Cell Therapy
  242. SMAanalytical
  243. Solvias
  244. Spectralys Biotech
  245. Spectrometry Cores, The Regents of the University of California
  246. STC Biologics
  247. Sumitomo Bakelite
  248. Sussex Research
  249. Symeres (formerly MercachemSyncom)
  250. Syngene
  251. Tacalyx
  252. tebu-bio
  253. Tentamus
  254. TG Therapeutics
  255. TheraProteins
  256. Thermo Fisher Scientific
  257. Tmunity Therapeutics
  258. Tubulis
  259. GlycoAnalytics Core, University of California
  260. United BioPharma
  261. United Therapeutics
  262. University of Adelaide
  263. University of Arkansas
  264. University of California
  265. University of Florida
  266. University of Georgia
  267. University of Nottingham
  268. University of Pittsburgh
  269. Proteomics Core, UT Southwestern Medical Center
  270. VelaLabs (Acquired by Tentamus)
  271. ViaMune
  272. VIMTA
  273. Vir Biotechnology
  274. Visterra (formerly Parasol Therapeutics)
  275. VProteomics
  276. VxP Biologics
  277. Washington University
  278. Waters
  279. Weill Cornell Medicine
  280. Wolfe Laboratories (Acquired by Pace Analytical Life Sciences)
  281. WuXi Biologics
  282. Z Biotech
  283. Zelle Biotechnology

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2023 Roots Analysis. All Rights Reserved.